XML 18 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Assets, Current
 3 Months Ended
Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Assets, Current Prepaid Expenses and Other Assets, Current
Prepaid expenses and other assets, current consisted of the following (in thousands):
March 31, 2021December 31, 2020
Research and development claims receivable$30,791 $24,711 
Prepayments7,477 10,206 
VAT receivable3,292 3,124 
Lease receivables from terminations4,480 1,237 
Grant income receivable411 414 
Other receivable257 199 
Deferred cost1,554 3,008 
     Total prepaid expenses and other current assets$48,262 $42,899 

The decrease in prepayments of $2.7 million as at March 31, 2021 when compared to December 31, 2020 is primarily related to decreases in prepayments for clinical trials and lower payments of directors' and officers liability insurance due to the timing of payments in the period when compared to the same period in the prior year.
The increase in research and development claims receivable is due to an increase in the effective tax rate when compared to the same period last year. More information on the movement in the tax position between periods can be found in Note 9.